Sargent Investment Group LLC Buys 1,322 Shares of Danaher Co. (NYSE:DHR)

Sargent Investment Group LLC increased its position in shares of Danaher Co. (NYSE:DHR) by 10.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,958 shares of the conglomerate’s stock after buying an additional 1,322 shares during the period. Sargent Investment Group LLC’s holdings in Danaher were worth $3,348,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Ninety One UK Ltd boosted its holdings in shares of Danaher by 3.4% during the 4th quarter. Ninety One UK Ltd now owns 134,189 shares of the conglomerate’s stock worth $30,803,000 after buying an additional 4,434 shares during the period. E. Ohman J or Asset Management AB boosted its holdings in shares of Danaher by 8.6% during the fourth quarter. E. Ohman J or Asset Management AB now owns 29,260 shares of the conglomerate’s stock worth $6,717,000 after acquiring an additional 2,310 shares during the period. Mather Group LLC. grew its position in shares of Danaher by 6.8% in the fourth quarter. Mather Group LLC. now owns 9,540 shares of the conglomerate’s stock valued at $2,190,000 after purchasing an additional 609 shares during the last quarter. Rockline Wealth Management LLC grew its holdings in Danaher by 5.6% in the 4th quarter. Rockline Wealth Management LLC now owns 6,713 shares of the conglomerate’s stock valued at $1,541,000 after buying an additional 356 shares in the last quarter. Finally, Compass Capital Management Inc. lifted its holdings in shares of Danaher by 4.8% during the fourth quarter. Compass Capital Management Inc. now owns 237,922 shares of the conglomerate’s stock worth $54,615,000 after buying an additional 10,994 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR stock opened at $215.05 on Wednesday. The firm has a market capitalization of $155.33 billion, a P/E ratio of 40.73, a P/E/G ratio of 2.80 and a beta of 0.83. Danaher Co. has a 52-week low of $210.04 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The stock has a 50 day moving average price of $234.93 and a 200 day moving average price of $252.88.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the firm earned $2.09 EPS. As a group, sell-side analysts predict that Danaher Co. will post 7.77 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.45%.

Insider Activity

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 10.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on DHR. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Raymond James restated a “market perform” rating on shares of Danaher in a research report on Monday. Stephens reaffirmed an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a research note on Wednesday, October 23rd. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a research note on Friday, December 13th. Finally, UBS Group cut their price target on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.